Suppr超能文献

血液系统恶性肿瘤患者中源自癌胚抗原-未成熟层粘连蛋白受体蛋白的HLA-A*0201呈递的T细胞表位的鉴定

Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.

作者信息

Siegel Sandra, Wagner Andreas, Friedrichs Birte, Wendeler Anneke, Wendel Lena, Kabelitz Dieter, Steinmann Jörg, Barsoum Adel, Coggin Joseph, Rohrer James, Dreger Peter, Schmitz Norbert, Zeis Matthias

机构信息

General Hospital St. Georg, Department of Hematology, Hamburg, Germany.

出版信息

J Immunol. 2006 Jun 1;176(11):6935-44. doi: 10.4049/jimmunol.176.11.6935.

Abstract

The oncofetal Ag immature laminin receptor (OFA-iLR) is a potential target molecule for immunotherapeutic studies in several tumor entities, including hematological malignancies. In the present study, we characterize two HLA-A0201-presented epitopes eliciting strong OFA-iLR peptide-specific human cytotoxic T cell (CTLs) responses in vitro. Both allogeneic HLA-A0201-matched and autologous CTLs recognized and killed endogenously OFA-iLR-expressing tumor cell lines and primary malignant cells from patients with hemopoietic malignancies in an MHC-restricted fashion but spared nonmalignant hemopoietic cells. Spontaneous OFA-iLR peptide-specific T cell reactivity was detectable in a significant proportion of leukemia patients. Interestingly, in patients with chronic lymphocytic leukemia and multiple myeloma but not in those with acute myeloid leukemia, significant frequencies of OFA peptide-specific CTLs could be detected in an early stage of disease but disappeared in patients with progressive disease. The identification of OFA-iLR-derived peptide epitopes provides a basis for tumor immunological studies and therapeutic vaccination strategies in patients with OFA-iLR-expressing malignancies.

摘要

癌胚抗原未成熟层粘连蛋白受体(OFA-iLR)是包括血液系统恶性肿瘤在内的多种肿瘤实体免疫治疗研究的潜在靶分子。在本研究中,我们鉴定了两种由HLA-A0201呈递的表位,它们在体外可引发强烈的OFA-iLR肽特异性人细胞毒性T细胞(CTL)反应。同种异体HLA-A0201匹配的CTL和自体CTL均以MHC限制的方式识别并杀伤内源性表达OFA-iLR的肿瘤细胞系以及血液系统恶性肿瘤患者的原发性恶性细胞,但对非恶性造血细胞无损伤。在相当比例的白血病患者中可检测到自发的OFA-iLR肽特异性T细胞反应性。有趣的是,在慢性淋巴细胞白血病和多发性骨髓瘤患者中,而不是急性髓系白血病患者中,在疾病早期可检测到显著频率的OFA肽特异性CTL,但在疾病进展的患者中消失。OFA-iLR衍生肽表位的鉴定为表达OFA-iLR的恶性肿瘤患者的肿瘤免疫学研究和治疗性疫苗接种策略提供了基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验